This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ISO IsoPlexis (ISO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About IsoPlexis Stock (NASDAQ:ISO) 30 days 90 days 365 days Advanced Chart Get IsoPlexis alerts:Sign Up Key Stats Today's Range$0.76▼$0.7650-Day Range$0.74▼$1.1352-Week Range$0.60▼$5.10VolumeN/AAverage Volume68,375 shsMarket Capitalization$30.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Read More… Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address ISO Stock News HeadlinesKarman Space & Defense Inaugurates New ISO 8 Clean Room for Spacecraft Assembly and Integration: Advancing Lunar and Space Missions with Flight-Proven SubsystemsApril 2, 2025 | businesswire.comTruecaller earns triple ISO certificationsNovember 5, 2024 | prnewswire.comFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Standard BioTools Inc.: Standard BioTools Announces Senior Leadership ChangesAugust 2, 2024 | finanznachrichten.deDiagnostic Industry Revelations: Comprehensive Analysis of Global Distribution Deals from 2016 to 2024 UnveiledMarch 5, 2024 | uk.finance.yahoo.comBruker to buy cell biology company PhenomeX for $108mAugust 18, 2023 | msn.comBruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX AcquisitionAugust 17, 2023 | msn.comPhenomeX stock rallies by 137% after buyout offer from BrukerAugust 17, 2023 | msn.comSee More Headlines ISO Stock Analysis - Frequently Asked Questions How were IsoPlexis' earnings last quarter? IsoPlexis Co. (NASDAQ:ISO) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($10.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by $9.87. The company had revenue of $4.19 million for the quarter, compared to analysts' expectations of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%. When did IsoPlexis IPO? IsoPlexis (ISO) raised $125 million in an initial public offering on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share. What other stocks do shareholders of IsoPlexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that IsoPlexis investors own include Biora Therapeutics (BIOR), NIO (NIO), PayPal (PYPL), Alibaba Group (BABA), Robinhood Markets (HOOD) and Lucid Group (LCID). Company Calendar Last Earnings11/10/2021Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:ISO CIK1615055 Webisoplexis.com Phone203-208-4111FaxN/AEmployees459Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net Margins-632.41% Pretax Margin-632.40% Return on Equity-127.86% Return on Assets-71.41% Debt Debt-to-Equity Ratio1.12 Current Ratio4.06 Quick Ratio2.50 Sales & Book Value Annual Sales$16.76 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.73Miscellaneous Outstanding Shares39,760,000Free Float37,218,000Market Cap$30.28 million OptionableNot Optionable Beta1.32 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ISO) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IsoPlexis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share IsoPlexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.